A Phase 1 interventional study of AZD5004 and Placebo in Healthy Participants, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-17.
Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies in Obesity by AstraZeneca — 8 open to participants now, 12 under way, 5 of them phase 3. Obesity · AstraZeneca.
Among the 52 studies in Obesity by AstraZeneca, this one is the 41st largest by enrollment of the 50 interventional ones that give a count, is one of 4 that started in 2024, is one of 24 in phase 1, and was the 30th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →8 of the 52 studies in Obesity by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Argentina, Brazil and 8 more countries
Ages 18+
AstraZeneca · Sites in China, Hong Kong, Malaysia and 2 more countries
Ages 18+
AstraZeneca · Sites in United States, Argentina, Australia and 13 more countries
Ages 18+
AstraZeneca · Sites in United States, Argentina, Australia and 13 more countries
Ages 18+
AstraZeneca · Sites in United States
Ages 18–55 · Healthy volunteers
By country, each count listing its studies:
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 19 · Phase 3 6 · Phase 4 1
First in 2004; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 31 is below the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 87 across the 50 interventional studies, 4,288 across the 2 observational. Of the 40 that completed or were terminated, 9 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
6 of the studies in Obesity by AstraZeneca that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07723833AstraZenecaA Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants | 2026-11-18 |
| NCT07534592AstraZenecaA Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants | 2027-01-25 |
| NCT06151964AstraZenecaA Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight | 2027-01-29 |
| NCT07511205AstraZenecaA Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity. | 2027-04-09 |
| NCT07911514AstraZenecaA Trial to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD9550 and AZD6234 | 2027-05-04 |
Add all 6 to your calendar (.ics) → With an account.
Among the 52 studies in Obesity by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to assess the safety, tolerability, and pharmacokinetic (PK) of AZD5004 administered as multiple oral doses in healthy participants and to compare the relative bioavailability of two oral tablet strengths of AZD5004.
This study comprises of 2 parts - Part A and Part B.
Part A is a placebo-controlled study to assess the safety, efficacy, tolerability, and PK of repeated dosing of AZD5004 compared with placebo.
Participants who are eligible according to the inclusion/exclusion criteria will be randomized to receive AZD5004 or matching placebo.
Part A will comprise:
Part B is a two-way cross-over study to compare the relative bioavailability of 2 oral tablet strengths of Formulation 1 (F1) of AZD5004.
The purpose of this study is to expand product knowledge between the 2 oral tablet strengths on plasma exposure levels to guide Phase 3 drug product development. The participants will be split into 2 groups. Group 1 will be dosed with Treatment 1 of AZD5004 and then dosed with Treatment 2 of AZD5004. Group 2 will be dosed with Treatment 2 of AZD5004 and then dosed with Treatment 1 of AZD5004.
Part B of the study will comprise:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive repeated dosing of AZD5004 orally.
Drug: AZD5004
Participants will receive matching Placebo orally.
Drug: Placebo
Participants in Group 1 will receive Treatment 1 of AZD5004 and then Treatment 2 of AZD5004. Participants in Group 2 will receive Treatment 2 of AZD5004 and then Treatment 1 of AZD5004.
Drug: AZD5004
Participants in Group 1 will receive Treatment 1 of AZD5004 and then Treatment 2 of AZD5004. Participants in Group 2 will receive Treatment 2 of AZD5004 and then Treatment 1 of AZD5004.
Drug: AZD5004
Participants will receive oral tablets of AZD5004 in Part A and Part B of the study as per arms they are assigned.
Also known as: ECC5004
Placebo will be administered as an oral tablet once daily.
Part A: Number of participants with adverse events (AEs) and serious adverse events (SAEs)
To assess the safety and tolerability of AZD5004 following oral multiple ascending doses in healthy participants.
Time frame: From screening (Day -28) to last follow up visit (Day 120)
Part B: Maximum observed plasma (peak) drug concentration (Cmax) of AZD5004
To evaluate the Cmax of 2 treatments of AZD5004 in healthy participants.
Time frame: From Day 1 (Treatment Period 1) to Day 13 (end of Treatment Period 2)
Part B: Area under the concentration-curve from time zero to the last quantifiable concentration (AUClast)
To evaluate the AUClast of 2 treatments of AZD5004 in healthy participants.
Time frame: From Day 1 (Treatment Period 1) to Day 13 (end of Treatment Period 2)
Part B: Area under concentration-time curve from time 0 to infinity (AUCinf)
To evaluate the AUCinf of 2 treatments of AZD5004 in healthy participants.
Time frame: From Day 1 (Treatment Period 1) to Day 13 (end of Treatment Period 2)
Part B: Time to reach maximum observed concentration (tmax)
To evaluate the tmax of 2 treatments of AZD5004 in healthy participants.
Time frame: From Day 1 (Treatment Period 1) to Day 13 (end of Treatment Period 2)
Part A: Maximum observed plasma (peak) drug concentration (Cmax) of AZD5004
To characterize the Cmax of multiple ascending doses of AZD5004 in healthy participants.
Time frame: From Day 1 to last follow up visit (Day 120)
Part A: Area under the concentration-curve from time zero to the last quantifiable concentration (AUClast)
To characterize the AUClast of multiple ascending doses of AZD5004 in healthy participants.
Time frame: From Day 1 to last follow up visit (Day 120)
Part A: Area under concentration time curve in the dosing interval (AUCtau)
To characterize the AUCtau of multiple ascending doses of AZD5004 in healthy participants.
Time frame: From Day 1 to last follow up visit (Day 120)
Part A: Amount of unchanged drug excreted into urine from time t1 to time t2 (Ae[t1-t2])
To characterize the Ae(t1-t2) of multiple ascending doses of AZD5004 in healthy participants.
Time frame: From Day 1 to last follow up visit (Day 120)
Part A: Percentage of dose excreted unchanged in urine from time t1 to time t2 (fe[t1-t2])
To characterize the fe(t1-t2) of multiple ascending doses of AZD5004 in healthy participants.
Time frame: From Day 1 to last follow up visit (Day 120)
Part A: Renal clearance (CLR)
To characterize the CLR of multiple ascending doses of AZD5004 in healthy participants.
Time frame: From Day 1 to last follow up visit (Day 120)
Part A: Percentage change from Baseline in body weight (kg)
To assess the effects of AZD5004 compared to placebo on body weight change from baseline.
Time frame: Baseline (Day - 2) to Days 49, 91, and 106
Part A: Absolute change from Baseline in body weight (kg)
To assess the effects of AZD5004 compared to placebo on body weight change from baseline.
Time frame: Baseline (Day - 2) to Days 49, 91, and 106
Part A: Percentage change from Baseline in Body Mass Index (BMI) (kg/m^2)
To assess the effects of AZD5004 compared to placebo on body weight change from baseline.
Time frame: Baseline (Day - 2) to Days 49, 91, and 106
Part A: Absolute change from Baseline in BMI (kg/m^2)
To assess the effects of AZD5004 compared to placebo on body weight change from baseline.
Time frame: Baseline (Day - 2) to Days 49, 91, and 106
Part B: Number of participants with adverse events (AEs) and serious adverse events (SAEs)
To evaluate the safety and tolerability of 2 treatments of AZD5004 in healthy participants.
Time frame: From screening (Day -28) to last follow up visit (Day 14)
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Ran from Aug 2024 to primary completion in Mar 2025, 6 months.
Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 6 months is below that.
Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elecoglipron